Q3 Loss Widens to $3.5M as Cash Drops to $8.5M; Two Trials Resume Enrollment
INTS is trading near its 52-week low of $3 (8.3% above the low) on light trading volume (0.3× avg).
Summary
Intensity Therapeutics posted a Q3 2026 net loss of $3.5M, wider than the $2.7M loss a year earlier on higher R&D costs, with cash down to $8.5M at September 30. The company raised only $1.5M net through its ATM in the quarter, and the release gives no cash runway estimate — with a going-concern warning already on the books, further financing looks likely. The clinical side is the brighter story: enrollment resumed in the Phase 3 INVINCIBLE-3 sarcoma study and the Phase 2 INVINCIBLE-4 breast cancer study, and preliminary data from 14 INVINCIBLE-4 patients showed pCR rates of 71% and 42% in the two cohorts. Those numbers come from just seven patients per cohort, so they are early and need confirmation. INVINCIBLE-4 enrollment is targeted for completion by end-2027, with an independent safety review planned for Q1 2027.
At the time of this announcement, INTS was trading at $3.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4M. The 52-week trading range was $3.00 to $15.75. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.